| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/30/2005 | WO2005059115A1 Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
| 06/30/2005 | WO2005059003A1 Novel polyesters |
| 06/30/2005 | WO2005058967A2 Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| 06/30/2005 | WO2005058958A2 Novel glp-1 analogues linked to albumin-like agents |
| 06/30/2005 | WO2005058935A2 Aqueous suspensions of ciclesonide for nebulisation |
| 06/30/2005 | WO2005058376A1 Polymeric micellar complexes and drug delivery vehicles thereof |
| 06/30/2005 | WO2005058367A2 Pegylated small molecules |
| 06/30/2005 | WO2005058366A2 Compositions comprising two different populations of polymer-active agent conjugates |
| 06/30/2005 | WO2005058365A1 Pharmaceutical preparation containing an antibody for the egf receptor |
| 06/30/2005 | WO2005058364A2 Preservative system |
| 06/30/2005 | WO2005058360A2 Radiation therapy and medical imaging using uv emitting nanoparticles |
| 06/30/2005 | WO2005058346A1 Stabilized interferon liquid formulations |
| 06/30/2005 | WO2005058312A1 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof |
| 06/30/2005 | WO2005058306A1 Glutamine-containing energy imparting amino acid composition or amino acid solution |
| 06/30/2005 | WO2005058297A1 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |
| 06/30/2005 | WO2005058283A2 Stabilised compositions of factor vii polypeptides |
| 06/30/2005 | WO2005058279A1 Biodegradable triblock copolymers as drugs solubilizing agents and method of use |
| 06/30/2005 | WO2005058278A1 Drug delivery compositions and methods |
| 06/30/2005 | WO2005058277A1 Injectable composition |
| 06/30/2005 | WO2005058276A1 Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having goog palatability |
| 06/30/2005 | WO2005058244A2 Novel anti-dc-sign antibodies |
| 06/30/2005 | WO2005058198A1 Therapeutic microparticles |
| 06/30/2005 | WO2005058153A2 Optical imaging contrast agents comprising a targeting vector linked to a fluorophore |
| 06/30/2005 | WO2005042560A3 Non-viral delivery of compounds to mitochondria |
| 06/30/2005 | WO2005042016A3 Stabilised compositions |
| 06/30/2005 | WO2005037247A3 Oral matrix formulations of doxazosin |
| 06/30/2005 | WO2005032401A3 Pressure-sensitive adhesive sheet for application to skin |
| 06/30/2005 | WO2005025508A3 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 06/30/2005 | WO2005021022A3 Stable formulations of peptides |
| 06/30/2005 | WO2005009369A3 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 06/30/2005 | WO2005004840A3 Non-gelatin film and method and apparatus for producing same |
| 06/30/2005 | WO2004112590A3 Methods of enhancing radiation effects with metal nanoparticles |
| 06/30/2005 | WO2004110392A3 Compositions and methods for treating coronavirus infection and sars |
| 06/30/2005 | WO2004078213A9 Composition for target substance introduction and method of target substance introduction |
| 06/30/2005 | WO2004012710A8 Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| 06/30/2005 | WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 06/30/2005 | US20050143484 Formed when exposed to base without requiring presence of second cross-linking reagent, redox catalyst, or radiation; for use as scaffolds in biological applications and tissue engineering |
| 06/30/2005 | US20050143476 Emulsion composite |
| 06/30/2005 | US20050143471 Mixtures of acetaminophen from about 0.1 to about 2.0% (w/w), neutralized carbopol from about 0.18 to about 0.60% (w/w) and polyethylene glycol having high viscocity; sweetening |
| 06/30/2005 | US20050143470 therapeutic treatment of Porcine Respiratory Disease Complex (PRDC) in pigs and Bovine Respiratory Syndrome (BRS) in calves; oral treatment; veterinary medicine |
| 06/30/2005 | US20050143461 inhibiting transmission of sexually transmitted diseases by applying a mixture of suramin sodium and a surfactant; including other active microbiocides, fungicides, viricides, bactericides, antifertility agents |
| 06/30/2005 | US20050143417 Dissolving difloxacin HCl and L-arginine base in a mixture of water, ethanol, propylene glycol, and optionally benzyl alcohol, at a pH of 9 to 10 and at a temperature of 10-30 degrees C.; minimized tissue damage or irritation at the injection site. |
| 06/30/2005 | US20050143408 Aporphine esters and their use in therapy |
| 06/30/2005 | US20050143366 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders |
| 06/30/2005 | US20050143342 Administering sulfated polysaccharide such as cellulose sulfate, dextran sulfate, dermatan sulfate, chondroitin sulfate, pentosan sulfate, fucoidin, mannan sulfate, dextrin sulfate, curdlan sulfate, chitin sulfate, heparin or heparin sulfate for therapy and prophylaxis of fungal infection |
| 06/30/2005 | US20050143333 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| 06/30/2005 | US20050143327 Used to ameliorate oxidative stress diseases eg neurodegenerative diseases |
| 06/30/2005 | US20050143325 Topical invermectin composition |
| 06/30/2005 | US20050143324 Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye |
| 06/30/2005 | US20050143321 Characterized by spontaneous increasing of the redox potential in relation to the potential of the hydrogen electrode; used in food industry, medicine, veterinary medicine, pharmaceutical industry, cosmetic industry, balneology, agriculture, fish farming |
| 06/30/2005 | US20050143312 Compositions and methods for promoting myocardial and peripheral angiogenesis |
| 06/30/2005 | US20050143303 Intranasal administration of glucose-regulating peptides |
| 06/30/2005 | US20050143301 Gycosylated at one or more sites. an immunoglobulin fusion.; treating scleroderma; polypeptides or mutein |
| 06/30/2005 | US20050143289 Botulinum toxin pharmaceutical composition |
| 06/30/2005 | US20050143283 with a chelating agent; improves the solution stability; lyophilized; antithrombotic agent |
| 06/30/2005 | US20050142639 Nucleotide sequence with vectors and administering apolipoproteins with data documents for binding lipids and cubulin for treatment of cardiovascular disorders |
| 06/30/2005 | US20050142636 Culturing yeast transformed with albumin-encoding nucleotide sequence in a fermentation medium; gene expression, separation, conditioning, adding sodium octanoate; cationic exchange chromatography, elution, ultrafiltration, sterilization, diafiltration, filling vessel |
| 06/30/2005 | US20050142578 Introducing library of siNA constructs into a biological system; determining nucleotide sequence of a siNA construct in which a process has been modulated; cellular proliferation, differentiation, morphology, angiogenesis, migration, viral multiplication; gene expression and engineering; transcription |
| 06/30/2005 | US20050142225 Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |
| 06/30/2005 | US20050142218 Therapy of wounds, including skin ulcers and post-operative trauma or burns; allows passage of nitric oxide to the skin |
| 06/30/2005 | US20050142204 Malaria; encapsulation in animal or plant oil |
| 06/30/2005 | US20050142200 Antimicrobial concentrates |
| 06/30/2005 | US20050142199 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core |
| 06/30/2005 | US20050142189 administering a hydrophilic alpha-tocopherol ester (especially d- alpha -tocopherol polyethylene glycol 1000 succinate) and paclitaxel; may contain polyethylene glycol or a oxypropylene-oxyethylene glycol nonionic block copolymer. |
| 06/30/2005 | US20050142188 Pellets having a core coated with an antifungal and a polymer |
| 06/30/2005 | US20050142186 Capsule comprising low-substituted cellulose ether and method for preparing the same |
| 06/30/2005 | US20050142184 Emulsion formulations for hydrophilic active agents |
| 06/30/2005 | US20050142181 Includes carrier for drug (anticancer agents; anti-sense oligonucleotide against epidermal growth factor receptor) and targeted ligand (benzamide derivative, anisamide) modifying the carrier to target the encapsulated drug to a sigma receptor over-expressed cell |
| 06/30/2005 | US20050142174 Adhesive and binding agent for dermal or transdermal treatment systems |
| 06/30/2005 | US20050142173 Testosterone hydroalcoholic gel for transdermal use; unique pharmacokinetic steady-state profile for testosterone |
| 06/30/2005 | US20050142167 Soluble highly branched glucose polymers and their method of production |
| 06/30/2005 | US20050142166 Fermenting food material comprising animal milk proteins (casein) or vegetable proteins with proteolytic lactic acid bacterium and lytic lactic acid bacterium (lactobacillus, lactococcus) |
| 06/30/2005 | US20050142152 Polymeric materials, their preparation and use |
| 06/30/2005 | US20050142141 Delivery of enzymes to the brain |
| 06/30/2005 | US20050142140 Immunoadhesin comprising a glycoprotein VI domain |
| 06/30/2005 | US20050142132 Prevention and treatment of amyloidogenic disease |
| 06/30/2005 | US20050142123 Comprising droplets of Coenzyme Q-10 dispersed in a matrix of a modified polysaccharide or a gelatin; supplement for human and animal nutrition |
| 06/30/2005 | US20050142117 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| 06/30/2005 | US20050142114 Preferentially targeting liposome to mammalian immune cell such as myeloid progenitor cell, monocyte, dendritic cell, macrophage or T-lymphocyte by administering to cell a liposome comprising an active agent and an outer surface that comprises a targeting ligand that binds marker on surface of cell |
| 06/30/2005 | US20050142110 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 06/30/2005 | US20050142105 Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| 06/30/2005 | US20050142098 Polyoxyethylene glycol conjugated neublastin polypeptide dimers; exhibit prolonged bioavailability |
| 06/30/2005 | US20050142097 Two different active drugs of same ionic charge conjugated with a single resin particle( cation exchange and anion exchage resin) without displacing the other, and without retarding the initial availability of either active; a barrier cellulose or methacrylic resin coating for controlled release |
| 06/30/2005 | US20050142076 Dental viscous pharmaceutical containing basic fibroblast growth factor |
| 06/30/2005 | US20050142073 Intranasal compositions |
| 06/30/2005 | US20050142072 Drug delivery into nose; controlling concentration into blood; using opioid or non-steroil antiinflammatory dryg |
| 06/30/2005 | US20050142071 Aerosol steroid solution formulation product with enhanced chemical resistance; container equipped with dispensing valve and having a corticosteroid of budesonide, triamcinolone acetonide, and/or rofleponide dissolved; internal surfaces coated with stainless steel, anodized aluminium or inert lining |
| 06/30/2005 | US20050142062 Novel method of diagnosing and treating gliomas |
| 06/30/2005 | US20050139808 redox systems for producing oxidized water, used as nontoxic antiseptics against microorganisms, including bacteria, viruses and fungi |
| 06/30/2005 | DE19725766B4 Formulierung zur Herstellung von Testsystemen und Herstellung der Formulierung Formulation for the preparation of test systems and the preparation of the formulation |
| 06/30/2005 | DE10357046A1 Kosmetische oder dermatologische Zubereitungen enthaltend eine Kombination aus grünem Farbstoff und antiinflammatorischem Wirkstoff Cosmetic or dermatological compositions comprising a combination of green dye and anti-inflammatory drug |
| 06/30/2005 | CA2550084A1 Stem cell targeting using magnetic particles |
| 06/30/2005 | CA2550050A1 Novel glp-1 analogues linked to albumin-like agents |
| 06/30/2005 | CA2549800A1 Novel anti-dc-sign antibodies |
| 06/30/2005 | CA2549593A1 Stabilised compositions of factor vii polypeptides |
| 06/30/2005 | CA2549038A1 Aqueous suspensions of ciclesonide for nebulisation |
| 06/30/2005 | CA2549011A1 Compositions comprising two different populations of polymer-active agent conjugates |
| 06/30/2005 | CA2548106A1 Therapeutic microparticles |
| 06/30/2005 | CA2548074A1 Injectable composition |
| 06/30/2005 | CA2547822A1 Stabilized interferon liquid formulations |